Medical Marijuana and Glaucoma

Written By

Brianna Tate

Understanding Glaucoma and Emerging Treatment Discussions

Glaucoma is a group of progressive eye diseases that damage the optic nerve, often due to increased intraocular pressure (IOP), and it is one of the leading causes of irreversible blindness worldwide. Effective glaucoma treatment focuses on lowering eye pressure to prevent optic nerve damage, typically through prescription eye drops, oral medications, laser therapy, or surgery.

In recent decades, researchers have explored the relationship between medical marijuana and glaucoma after studies suggested cannabinoids, particularly THC, may temporarily reduce intraocular pressure. This discovery has generated interest in cannabis for glaucoma treatment, although medical organizations emphasize that conventional therapies remain the most reliable option for long-term glaucoma management.

What Is Glaucoma?

Glaucoma is a group of eye diseases that damage the optic nerve, which carries visual information from the eye to the brain. This damage is often linked to increased intraocular pressure (IOP) caused by improper drainage of aqueous humor, the fluid that helps maintain normal eye pressure. Over time, elevated pressure can damage optic nerve fibers, leading to progressive vision loss and potentially permanent blindness if left untreated.

The most common form, primary open-angle glaucoma, develops gradually as the eye’s drainage system becomes less efficient. Angle-closure glaucoma occurs when the drainage angle becomes blocked, causing a rapid increase in eye pressure. Another form, normal-tension glaucoma, can damage the optic nerve even when eye pressure appears normal.

Several factors increase the risk of developing glaucoma, including older age, a family history of the disease, consistently high eye pressure, and underlying health conditions such as diabetes or cardiovascular disease. Because symptoms often develop slowly and early vision loss may go unnoticed, routine eye exams and early detection are essential for protecting long-term vision.

How Cannabis Affects the Body and the Endocannabinoid System

The endocannabinoid system (ECS) is a cell-signaling network that helps regulate many functions in the body, including pain, inflammation, mood, appetite, and eye health. The ECS operates through specialized receptors called CB1 and CB2, which interact with both naturally produced endocannabinoids and cannabinoids found in cannabis.

These receptors are located throughout the brain, nervous system, immune cells, and various organs, helping maintain internal balance, also known as homeostasis. When cannabinoids enter the body, they can influence these receptors and alter certain physiological responses, which is why cannabis can affect mood, perception, appetite, and pain signaling.

Cannabinoid receptors are also present in ocular tissues such as the retina, ciliary body, and optic nerve. This has led researchers to study the potential relationship between medical marijuana and glaucoma. Compounds such as THC (tetrahydrocannabinol) can bind to CB1 receptors and may temporarily influence intraocular pressure, while CBD (cannabidiol) interacts with the ECS differently and may affect inflammation and other regulatory processes.

Cannabis and Intraocular Pressure (IOP)

Scientific interest in cannabis and glaucoma began in the 1970s when researchers discovered that THC could temporarily reduce intraocular pressure. Because elevated IOP is a major risk factor for glaucoma progression, this finding prompted further research into whether cannabis could play a role in glaucoma treatment.

Studies have shown that cannabis can lower eye pressure by influencing cannabinoid receptors involved in fluid production and drainage within the eye. In some patients, this effect can reduce IOP by approximately 20 to 30 percent. However, the pressure-lowering effects typically last only three to four hours. Maintaining consistent eye pressure control would therefore require frequent dosing throughout the day.

In contrast, standard glaucoma medications such as prescription eye drops are designed to provide longer-lasting pressure reduction with fewer systemic effects. For this reason, researchers continue to explore whether cannabinoids could eventually be developed into more targeted glaucoma therapies.

Scientific Research and Clinical Evidence

Early research, including studies supported by the National Eye Institute, confirmed that cannabis can reduce intraocular pressure for short periods of time. However, evaluations from organizations such as the American Academy of Ophthalmology show that these effects are brief and inconsistent when compared with established glaucoma treatments.

Current medical evidence indicates that although cannabis can influence eye pressure, it does not provide the stable and sustained pressure control required for effective glaucoma management. As a result, most medical experts do not consider cannabis a reliable primary treatment for the disease.

Risks, Limitations, and Medical Concerns

Although cannabis may temporarily lower intraocular pressure, several limitations and health concerns make it difficult to use as a long-term glaucoma treatment. The short duration of its effects would require repeated dosing throughout the day to maintain stable eye pressure levels.

Regular cannabis use may also produce side effects such as dizziness, cognitive impairment, and increased heart rate. These effects can be particularly concerning for older adults, who are more likely to develop glaucoma. In addition, cannabis can lower systemic blood pressure, which may reduce blood flow to the optic nerve and potentially worsen damage in some patients.

Because of these concerns, medical experts generally recommend that patients rely on clinically approved glaucoma treatments and consult a healthcare professional before considering cannabis as part of their care.

Current Medical Consensus and Future Research

Established treatments such as prescription medications, laser procedures, and surgical interventions remain the most effective ways to slow glaucoma progression and protect vision. However, ongoing research into the endocannabinoid system and eye health continues to improve scientific understanding of how cannabinoids interact with ocular tissues.

Future studies may lead to the development of targeted cannabinoid-based therapies, including specialized eye drops or synthetic compounds designed to safely and consistently reduce intraocular pressure. While cannabis itself is not currently recommended as a primary treatment, continued research may help scientists identify new therapeutic approaches for glaucoma in the future.

References

Brianna Tate
Brianna Tate is a cannabis industry writer and columnist who shares her expertise in retail, product development, and operations through contributions to leading business platforms. In addition to her editorial work, she collaborates with cannabis companies and brands to provide operational insight, strategic guidance, and industry-informed content that supports sustainable growth.